Danaher Corporation $DHR Holdings Cut by Arthur M. Cohen & Associates LLC

Key Points

• Arthur M. Cohen & Associates LLC reduced its stake in Danaher Corporation by 8.8% in Q2, now holding approximately 188,132 shares valued at $37.16 million.
• Danaher stock has a market capitalization of $138.42 billion and reported a quarterly earnings per share (EPS) of $1.80, exceeding estimates and reflecting a revenue increase of 3.4% year-over-year.
• Several brokerages have adjusted their price targets for Danaher, with Scotiabank upgrading it to a "sector outperform" rating and setting a new target price of $275.00.

Arthur M. Cohen & Associates LLC lessened its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 8.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 188,132 shares of the conglomerate's stock after selling 18,079 shares during the quarter. Danaher makes up about 6.6% of Arthur M. Cohen & Associates LLC's holdings, making the stock its 3rd largest position. Arthur M. Cohen & Associates LLC's holdings in Danaher were worth $37,164,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. GHP Investment Advisors Inc. lifted its position in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC purchased a new stake in shares of Danaher during the 4th quarter valued at $27,000. Sierra Ocean LLC boosted its position in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in Danaher in the 1st quarter worth $31,000. Finally, Dunhill Financial LLC raised its stake in shares of Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft cut their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Barclays reissued an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Guggenheim restated a "buy" rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Robert W. Baird upped their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research report on Friday, July 18th. Finally, Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research note on Tuesday, September 2nd. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $246.35.

Danaher Price Performance

Shares of DHR stock traded down $1.96 during trading on Friday, hitting $193.31. The company had a trading volume of 5,932,115 shares, compared to its average volume of 3,371,563. The stock has a market capitalization of $138.42 billion, a price-to-earnings ratio of 41.13, a price-to-earnings-growth ratio of 2.70 and a beta of 0.75. The stock's 50-day moving average is $200.17 and its two-hundred day moving average is $198.18. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.